Clinical Trial Update: Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial assessed nivolumab as maintenance therapy in newly diagnosed primary central nervous system lymphoma with persistent CSF circulating…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Primary Central Nervous System Lymphoma (PCNSL) | Phase 2 | Status: COMPLETED